对比紫杉醇联合顺铂两种给药方法用于治疗晚期卵巢癌的疗效
|
摘要
目的对比紫杉醇联合顺铂两种给药方法用于治疗晚期卵巢癌的疗效。方法随机选取2011年5月至2017年5月延安大学附属医院收治的晚期卵巢癌患者60例,依据紫杉醇联合顺铂给药方法将这些患者分为腹腔给药组(n=30)和静脉给药组(n=30)两组,统计分析两组患者的临床疗效、不良反应发生情况。结果腹腔给药组患者的总缓解率63. 3%(19/30)显著高于静脉给药组30. 0%(9/30),差异具有统计学意义(P <0. 05),但两组患者的恶心呕吐、腹痛腹泻、乏力、脱发、贫血、血小板减少、白细胞减少、肌肉关节疼痛等不良反应发生率46. 7%(14/30)、40. 0%(12/30)、36. 7%(11/30)、36. 7%(11/30)、46. 7%(14/30)、43. 3%(13/30)、70. 0%(21/30)、30. 0%(9/30) vs53. 3%(16/30)、46. 7%(14/30)、33. 3%(10/30)、36. 7%(11/30)、53. 3%(16/30)、46. 7%(14/30)、70. 0%(21/30)、33. 3%(10/30)之间的差异无统计学意义(P> 0. 05)。结论紫杉醇联合顺铂腹腔给药用于治疗晚期卵巢癌的疗效较静脉给药显著。
Objective To compare the efficacy of two administration methods of paclitaxel combined with cisplatin in the treatment of advanced ovarian cancer. Methods 60 patients with advanced ovarian cancer in our hospital from May 2011 to May 2017 were randomly selected and divided into intraperitoneal administration group( n = 30) and intravenous injection group( n = 30). The clinical curative effects and incidence of adverse reactions of the two groups were statistically analyzed. Results The remission rate of intraperitoneal administration group( 63. 3%,19/30) was significantly higher than that of intravenous injection group( 30. 0%,9/30)( P < 0. 05),but the differences in incidence rates of nausea and vomiting,abdominal pain,diarrhea,fatigue,alopecia,anemia,thrombocytopenia,leukopenia,muscle and joint pain between the two groups were not significant( P > 0. 05).Conclusions The efficacy of intraperitoneal administration of paclitaxel combined with cisplatin in the treatment of advanced ovarian cancer is more significant than intravenous injection.
Objective To compare the efficacy of two administration methods of paclitaxel combined with cisplatin in the treatment of advanced ovarian cancer. Methods 60 patients with advanced ovarian cancer in our hospital from May 2011 to May 2017 were randomly selected and divided into intraperitoneal administration group( n = 30) and intravenous injection group( n = 30). The clinical curative effects and incidence of adverse reactions of the two groups were statistically analyzed. Results The remission rate of intraperitoneal administration group( 63. 3%,19/30) was significantly higher than that of intravenous injection group( 30. 0%,9/30)( P < 0. 05),but the differences in incidence rates of nausea and vomiting,abdominal pain,diarrhea,fatigue,alopecia,anemia,thrombocytopenia,leukopenia,muscle and joint pain between the two groups were not significant( P > 0. 05).Conclusions The efficacy of intraperitoneal administration of paclitaxel combined with cisplatin in the treatment of advanced ovarian cancer is more significant than intravenous injection.
引文
[1]刘睿,曹晓艳,肖颖,等.奈达铂联合吉西他滨治疗老年复发性卵巢癌的疗效[J].中国老年学杂志,2012,32(10):3190-3191.
[2]刘兵,白洋,张立,等.紫杉醇联合顺铂对人卵巢癌耐药细胞株SKOV3/DDP耐药性的逆转作用[J].中国妇幼保健,2013,18(28):3009-3011.
[3]王双月.紫衫醇联合不同铂类药物化疗在晚期卵巢癌中的疗效和安全性研究[J].中国医学装备,2014,11(5):68-69.
[4]崔开颖,朱根海,杨舒盈.紫杉醇联合顺铂静脉腹腔化疗治疗晚期卵巢癌的疗效分析[J].中国肿瘤临床与康复,2013,20(5):498-500.
[5]崔开颖,朱根海,杨舒盈.紫杉醉联合顺铂静脉腹腔化疗治疗晚期卵巢癌的疗效分析[J].中国肿瘤临床与康复,2013,30(5):498-501.
[6]齐聪,张勤华,李久现.增免抑瘤方联合顺铂对铂类耐药卵巢癌抑瘤率影响的实验研究[J].中国中西医结合杂志,2012,23(6):818-820.
[7]梁媛,刘佳丽,张振勇,等.复发性卵巢癌不同化疗方案临床疗效的Meta分析[J].中华肿瘤防治杂志,2011,18(6):453-456.
[8]代小松. CA125检测对良恶性腹水的鉴别诊断[J].实用医院临床杂志,2011,8(5):102-103.
[9]叶冬云.紫杉醇联合顺铂腹腔热灌注化疗治疗晚期卵巢癌的疗效观察[J].临床和实验医学杂志,2014,13(10):838-840.
[10]梁若笳.增免抑瘤方辅助治疗对晚期卵巢癌术后化疗不良反应和患者生存质量的影响[J].中华中医药学刊,2013,31(11):2588-2590.
[11]谭敏.桂枝茯苓丸辅助化疗治疗卵巢癌患者28例临床观察[J].肿瘤药学,2011,1(6):520-523.
[12]陈藕景,祝莹.血清肿瘤标志物在卵巢癌早期诊断中的临床价值[J].中国性科学,2016,25(3):48-50.
[13]孙洁,杨素芬,白图门,等.卵巢癌患者腹水及外周血CD4+CD25+调节性T细胞含量及抑制功能的研究[J].中国性科学,2016,25(2):17-19.
[14]周敏巧,梁文霞,郑君珍等.血清癌抗原125、甲胎蛋白、癌胚抗原联合检测对女性恶性肿瘤的诊断价值[J].中国性科学,2015,24(1):55-57.
[15]甘露,陈燕,刘荣,等. HE4和CA125水平变化在卵巢癌术后疗效评估中的应用价值研究[J].中国性科学,2016,25(12):50-53.
[16] Sato S,Fujiwara H,Oishi T,et al. Evaluation of a formula for individual dosag-e of nedaplatin based on renal function[J]. Cancer Chemother Phannacol,2012,69(3):599-603.
[17] Kim SW,Paek J,Nam EJ,et al. The feasibility of carboplatinbased intraperitoneal chemotherapy in ovarian cancer[J]. Eur J Obstet Gynecol Reprod Biol,2010,152(2):195-199.
[18] Hogberg T. Chemotherapy:Current drugs still have potential in advanced ovarian cancer[J]. Nat Rev Clin Oncol,2010,7(4):191-193.
[2]刘兵,白洋,张立,等.紫杉醇联合顺铂对人卵巢癌耐药细胞株SKOV3/DDP耐药性的逆转作用[J].中国妇幼保健,2013,18(28):3009-3011.
[3]王双月.紫衫醇联合不同铂类药物化疗在晚期卵巢癌中的疗效和安全性研究[J].中国医学装备,2014,11(5):68-69.
[4]崔开颖,朱根海,杨舒盈.紫杉醇联合顺铂静脉腹腔化疗治疗晚期卵巢癌的疗效分析[J].中国肿瘤临床与康复,2013,20(5):498-500.
[5]崔开颖,朱根海,杨舒盈.紫杉醉联合顺铂静脉腹腔化疗治疗晚期卵巢癌的疗效分析[J].中国肿瘤临床与康复,2013,30(5):498-501.
[6]齐聪,张勤华,李久现.增免抑瘤方联合顺铂对铂类耐药卵巢癌抑瘤率影响的实验研究[J].中国中西医结合杂志,2012,23(6):818-820.
[7]梁媛,刘佳丽,张振勇,等.复发性卵巢癌不同化疗方案临床疗效的Meta分析[J].中华肿瘤防治杂志,2011,18(6):453-456.
[8]代小松. CA125检测对良恶性腹水的鉴别诊断[J].实用医院临床杂志,2011,8(5):102-103.
[9]叶冬云.紫杉醇联合顺铂腹腔热灌注化疗治疗晚期卵巢癌的疗效观察[J].临床和实验医学杂志,2014,13(10):838-840.
[10]梁若笳.增免抑瘤方辅助治疗对晚期卵巢癌术后化疗不良反应和患者生存质量的影响[J].中华中医药学刊,2013,31(11):2588-2590.
[11]谭敏.桂枝茯苓丸辅助化疗治疗卵巢癌患者28例临床观察[J].肿瘤药学,2011,1(6):520-523.
[12]陈藕景,祝莹.血清肿瘤标志物在卵巢癌早期诊断中的临床价值[J].中国性科学,2016,25(3):48-50.
[13]孙洁,杨素芬,白图门,等.卵巢癌患者腹水及外周血CD4+CD25+调节性T细胞含量及抑制功能的研究[J].中国性科学,2016,25(2):17-19.
[14]周敏巧,梁文霞,郑君珍等.血清癌抗原125、甲胎蛋白、癌胚抗原联合检测对女性恶性肿瘤的诊断价值[J].中国性科学,2015,24(1):55-57.
[15]甘露,陈燕,刘荣,等. HE4和CA125水平变化在卵巢癌术后疗效评估中的应用价值研究[J].中国性科学,2016,25(12):50-53.
[16] Sato S,Fujiwara H,Oishi T,et al. Evaluation of a formula for individual dosag-e of nedaplatin based on renal function[J]. Cancer Chemother Phannacol,2012,69(3):599-603.
[17] Kim SW,Paek J,Nam EJ,et al. The feasibility of carboplatinbased intraperitoneal chemotherapy in ovarian cancer[J]. Eur J Obstet Gynecol Reprod Biol,2010,152(2):195-199.
[18] Hogberg T. Chemotherapy:Current drugs still have potential in advanced ovarian cancer[J]. Nat Rev Clin Oncol,2010,7(4):191-193.